Jade Biosciences, Inc. (JBIO)

NASDAQ: JBIO · Real-Time Price · USD

8.48

+0.42 (5.21%)

At close: Sep 26, 2025, 4:00 PM EDT

8.32

-0.16 (-1.89%)

After-hours: Sep 26, 2025, 4:28 PM EDT

5.21% (1D)

Market Cap	276.67M
Revenue (ttm)	n/a
Net Income (ttm)	-93.96M
Shares Out	32.63M
EPS (ttm)	-18.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,561
Open	8.06
Previous Close	8.06
Day's Range	7.77 - 8.51
52-Week Range	1.92 - 13.50
Beta	n/a
Analysts	Strong Buy
Price Target	16.00 (+88.68%)
Earnings Date	Nov 5, 2025

About JBIO

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. The company has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. was founded in 2024 and is headquartered in Waltham, Mas... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2024

Employees 30

Stock Exchange NASDAQ

Ticker Symbol JBIO

Website https://jadebiosciences.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for JBIO stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 88.68% from the latest price.

Price Target

$16.0

(88.68% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic ...

25 days ago - GlobeNewsWire

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...

4 weeks ago - GlobeNewsWire

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy...

6 weeks ago - GlobeNewsWire

Jade Biosciences to Participate in Two Upcoming Investor Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...

2 months ago - GlobeNewsWire

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...

3 months ago - GlobeNewsWire

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 sh...